June 23, 2025

Sitting-Rising Test Predicts Long-Term Mortality Risk

A 12-year study of over 4,000 adults found that poor performance on a basic sitting and rising test was strongly linked to increased risk of death from natural and cardiovascular causes.

Conexiant

June 23, 2025

Psoriasis Biologics May Reduce Heart Risks

A large international study found that psoriasis patients treated with biologic therapies had a significantly lower risk of cardiovascular disease compared to those receiving oral treatments.

Conexiant

June 20, 2025

Gut Bacteria Predict Chemotherapy-Related Heart Damage

Specific gut bacteria correlate with biomarkers indicating increased risk of cardiotoxicity in breast cancer patients before chemotherapy treatment.

Conexiant

June 19, 2025

Heavy Drinking Consistently Linked To Heart Risks

New research finds that heavy alcohol consumption consistently raises cardiovascular risks, while evidence for protective effects of light drinking remains inconclusive.

Conexiant

June 19, 2025

Plaque Calcification May Predict Future Hemorrhage Risk

New research tracked subclinical carotid plaque changes over six years and found that plaques with calcification were twice as likely to develop intraplaque hemorrhage, with men showing greater risk for complex plaque progression.

Conexiant

June 17, 2025

Is Stroke Risk Lower with Semaglutide?

Semaglutide lowered stroke risk compared to empagliflozin in adults with type 2 diabetes, though overall mortality and heart attack rates were similar between the two drugs.

Conexiant

June 16, 2025

Can Gout Therapy Protect Hearts Too?

New research shows achieving serum urate targets within1 year may significantly reduce major cardiovascular events in gout patients.

Conexiant

June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 13, 2025

Obicetrapib May Offer LDL Benefit

In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.

Conexiant